Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019
Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

News
novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019
Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …

News
lilly_entrance_web

Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …

News

Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype

May 22, 2019
Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma

Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …

News
amgen_flag

Amgen agrees to buy Nuevolution for $167 million

May 22, 2019
Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma

California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …

News
merckwindow_web

MSD buys Peloton Therapeutics in deal worth $2.1 billion

May 22, 2019
Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …

News

Children wait six and half years longer than adults for new cancer drugs, study says

May 22, 2019
Research and Development Cancer, FDA, children, oncology, paediatrics, pharma

Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston …

News
merck-keytruda

Keytruda fails to improve overall survival in advanced triple-negative breast cancer

May 21, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer

MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …

News
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …

News
roche__tree

Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

May 17, 2019
Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …

News

Insider Interview: Paving paths in prostate cancer

May 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …

Feature
5204602349_c87b204860_z

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019
Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …

News

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019
Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …

News
merck-keytruda

MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …

News

Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua

May 8, 2019
Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026